Actio Biosciences was founded on an understanding that developing new drugs for rare diseases can inform novel treatment approaches for common diseases.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $121M
Investors 2
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
| 10.07.2026 | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.06.2025 | Series B | $66M | - |
| 14.09.2023 | Series A | $55M | - |
Mentions in press and media 4
| Date | Title | Description |
| 19.06.2025 | Actio Biosciences Raises $66M in Series B Financing | Actio Biosciences, a San Diego, CA-based clinical-stage biotechnology company which specializes in genetics and precision medicine, raised $66M in Series B funding. The round was led by Regeneron Ventures and current investor Deerfield Mana... |
| 18.06.2025 | Actio Biosciences Secures $66 Million Series B Financing | SAN DIEGO, CA, Actio Biosciences, a clinical-stage biotechnology company, announced the closing of a $66 million Series B financing. >> Click here for more funding data on Actio Biosciences >> To export Actio Biosciences fundin... |
| 14.09.2023 | Actio Biosciences Closes $55M Series A Financing | Actio Biosciences, a San Diego, CA-based biotechnology company, closed a $55m Series A financing. The round was led by Canaan and DROIA Ventures, with participation from existing investors Deerfield Management and EcoR1, as well as new inve... |
| - | Actio Biosciences | “At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and ... |